EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer

Masanobu Takahashi iD, Sakura Hiraide Taniguchi, Yuya Yoshida

Cancer Science · 2026-11 · 117 (11) · 2901-2909

DOI: 10.1111/cas.70480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 23.07.2026. Verfasst von Masanobu Takahashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Neoplasms, Protein Kinase Inhibitors, Mutation. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF is a key oncogene in various malignancies including malignant melanoma, thyroid cancer, colorectal cancer, and lung cancer. The protein it encodes is a constituent of the mitogen‐activated protein kinase pathway that regulates cell growth. Mutations, mainly BRAF V600E , that cause the activation of BRAF in turn induce MEK and ERK activation through their phosphorylation, which promotes the growth and survival of cancer cells. Treatment with BRAF inhibitor, and more recently, treatment with BRAF inhibitor plus MEK inhibitor was first developed in malignant melanoma. In 2022, treatment with BRAF inhibitor plus MEK inhibitor was approved tumor‐agnostically for the treatment of BRAF V600E ‐mutated cancer, apart from colorectal cancer, in the USA. In colorectal cancer, the combination of a BRAF inhibitor and an anti‐EGFR antibody was developed in a later line setting, and more recently, the combination of a BRAF inhibitor, an anti‐EGFR antibody and chemotherapy was developed. Despite the recent advances of BRAF‐targeted therapies, intrinsic and/or acquired resistance to those therapies still needs to be overcome. We discuss the current status of the clinical development of BRAF‐targeted therapy, clinical findings on the resistance mechanism, and new possible treatment strategies for patients with BRAF ‐mutated cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafNeoplasmsProtein Kinase InhibitorsMutationHumansDrug Resistance, NeoplasmMolecular Targeted TherapyErbB Receptors

Stichwörter der Autor:innen

BRAFBRAF inhibitorBRAF‐mutated cancerMEK inhibitoranti‐EGFR antibody

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, humanErbB Receptors

Autor:innen und Institutionen

  • Department of Clinical Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

ORCID-Profile: Masanobu Takahashi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Takahashi, M., Taniguchi, S. H., & Yoshida, Y. (2026). New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer. Cancer Science, 117(11), 2901-2909. https://doi.org/10.1111/cas.70480

Vancouver

Takahashi M, Taniguchi SH, Yoshida Y. New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer. Cancer Science. 2026;117(11):2901-2909. doi:10.1111/cas.70480

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Masanobu and Taniguchi, Sakura Hiraide and Yoshida, Yuya},
  title = {New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {11},
  pages = {2901--2909},
  doi = {10.1111/cas.70480}
}
Kostenlos starten →